Dose escalation based on (18)F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)

INTRODUCTION: Definitive chemoradiotherapy has established the standard non-surgical treatment for locally advanced esophageal cancer. The standard dose of 50–50.4 Gy has been established decades ago and been confirmed in modern trials. The theorical advantage of better local control and technical a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hongcheng, Liu, Qiufang, Xu, Hao, Mo, Miao, Wang, Zezhou, Lu, Kui, Zhou, Jialiang, Chen, Junqiang, Zheng, Xiangpeng, Ye, Jinjun, Ge, Xiaolin, Luo, Honglei, Liu, Qi, Deng, Jiaying, Ai, Dashan, Hao, Shengnan, Zhang, Junhua, Tseng, I Hsuan, Song, Shaoli, Chen, Yun, Zhao, Kuaile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338557/
https://www.ncbi.nlm.nih.gov/pubmed/35906623
http://dx.doi.org/10.1186/s13014-022-02099-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338557/
https://www.ncbi.nlm.nih.gov/pubmed/35906623
http://dx.doi.org/10.1186/s13014-022-02099-y

Ejemplares similares